EGFR and cholangiocarcinoma: Hence, we moved forward the trial of CART-EGFR immunotherapy (NCT01869166) in advanced unresectable/metastatic CCA following the safety and feasibility evaluation of CART-EGFR therapy in advanced non-small cell lung cancer [13].